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Abstract
Telomere function is essential to maintaining the physical integrity of linear chromosomes and healthy human aging. The
probability of forming proper telomere structures depends on the length of the telomeric DNA tract. We attempted to
identify common genetic variants associated with log relative telomere length using genome-wide genotyping data on
3,554 individuals from the Nurses’ Health Study and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial that
took part in the National Cancer Institute Cancer Genetic Markers of Susceptibility initiative for breast and prostate cancer.
After genotyping 64 independent SNPs selected for replication in additional Nurses’ Health Study and Women’s Genome
Health Study participants, we did not identify genome-wide significant loci; however, we replicated the inverse association
of log relative telomere length with the minor allele variant [C] of rs16847897 at the TERC locus (per allele b=20.03,
P = 0.003) identified by a previous genome-wide association study. We did not find evidence for an association with variants
at the OBFC1 locus or other loci reported to be associated with telomere length. With this sample size we had .80% power
to detect b estimates as small as 60.10 for SNPs with minor allele frequencies of $0.15 at genome-wide significance.
However, power is greatly reduced for b estimates smaller than 60.10, such as those for variants at the TERC locus. In
general, common genetic variants associated with telomere length homeostasis have been difficult to detect. Potential
biological and technical issues are discussed.
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Introduction
Two major challenges are encountered in maintaining the
physical integrity of linear chromosomes. First, cells must prevent
the recognition of chromosome ends as double-stranded DNA
breaks [1]. Second, telomeric ends are lost with each cell division
as a result of the end replication problem [2]. On average, human
telomeres lose 50 to 100 bp per mitotic division, which limits the
replicative capacity of a cell [3]. To overcome these issues,
eukaryotic cells evolved the telomere maintenance system, the
almost universal mechanism used to protect chromosome ends [4].
Telomeres are complex dynamic nucleoprotein structures that
consist of a long stretch of hexameric (TTAGGG)n DNA repeats, a
single-stranded G-rich 39 overhang, the telomerase enzyme
complex, six telomere-specific proteins, and other telomere-
associated proteins including those of the DNA repair machinery
[5]. In normal mitotic cells, telomeres switch between capped and
uncapped states [6]. Telomere-associated proteins assist the single-
stranded G-rich 39 overhang in invading the double-stranded
telomeric tract to form a large terminal loop. This conformation
contributes to the functional capped structure of the telomeric end,
inhibiting the DNA damage response [7]. Telomerase, a highly
conserved enzyme consisting of protein [telomerase reverse
transcriptase (TERT), dyskerin (DKC1)] and RNA [telomerase
RNA component (TERC)] components [8], appends chromosome
ends with hexameric repeats to restore telomere length [9] and
plays a role in stabilizing telomeres in the capped state [6].
The likelihood of a telomere existing in an uncapped vs. a
capped state is dependent on telomere length. Longer telomeres
are more likely to form the protective capped structure than
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shorter telomeres [6]. In germ cells, strong telomerase expression
maintains long telomere lengths [10]. Telomerase activity has
been detected at lower levels in fibroblasts, peripheral blood
leukocytes, skin, hair follicles, intestinal crypts, and endometrium.
In these tissues, expression levels are not sufficient to prevent
replication-associated telomere attrition [11–15]. As a result,
telomere length declines with age [16–21]. As telomeres shorten
and become dysfunctional, the uncapped chromosomal ends
undergo nucleolytic decay, chromosomal end-to-end fusions, and
atypical recombination triggering senescence or apoptosis [22].
Diseases characterized by telomere dysfunction highlight the
importance of telomere maintenance for healthy human aging.
Patients with dyskeratosis congenita, a rare inherited bone marrow
failure and cancer predisposition syndrome, have very short
germline telomeres (,1st percentile for age), and approximately
one-half have a mutation in a known telomere biology gene [23].
Patients with the shortest telomeres exhibit the most severe
phenotypes [24]. Telomere attrition, genomic instability, and
premature senescence are also features of Hutchinson-Gilford
progeria syndrome and Werner syndrome [25]. Shorter leukocyte
telomere length has been implicated in a number of common
aging-related diseases such as cancer [26–30] and cardiovascular
disease [31–36] as well as increased mortality [37–41].
Despite the essential role telomeres play in the maintenance of
normal cellular function, little is known about the common genetic
determinants of telomere length. Heritability estimates from family
and twin studies for telomere length range from 36% to 86%
[17,40–45]. Telomere lengths in different tissues are significantly
correlated, with far less variation between tissues from the same
individual compared to variation between individuals of a
particular tissue type [18,20,21,46–48]. Quantitative trait linkage
analyses identified significant linkage to chromosomes 12p11.2
[43,49], and 14q23.2 [44], but these loci have not been replicated
in independent studies [44,50–52]. Common genetic variants in
known telomere maintenance genes do not exhibit strong
influences on telomere length [45,53–55]. Genome-wide associa-
tion studies (GWAS) have identified and replicated associations at
the TERC locus, which account for no more than 1% of variation
in telomere length [51,52]. Variants at the oligonucleotide/
oligosaccharide-binding fold containing 1 (OBFC1) gene locus,
which codes for a protein that interacts with telomere-specific
proteins and is implicated in telomere length regulation [56], were
also recently identified using a meta-analysis of GWAS cohorts
[52]. To identify additional variants associated with telomere
length, we conducted a GWAS using data from two large cohorts
that took part in the National Cancer Institute Cancer Genetic
Markers of Susceptibility (CGEMS) initiative for breast and
prostate cancer.
Results
We used a two-stage GWAS to identify common genetic
variants associated with log relative telomere length. Age, smoking,
and mean log relative telomere length values of each population
are shown in Table 1. The GWAS discovery set included
genotypes for 519,076 SNPs on a total of 3554 individuals from
the Nurses’ Health Study (NHS) and the Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial. After
adjusting for the top principal components of genetic variation
from each cohort, the distribution of the observed P values does
not suggest any inflation in Type 1 error rates due to population
stratification or other sources of bias (Figure 1).
None of the P values observed in the first stage of our GWAS
reached the genome-wide significance level of P,5.061028 [57].
The SNP most significantly associated with log relative telomere
length in this discovery set was rs1978423, located upstream of the
pyroglutamyl-peptidase I (PGPEP1) and LSM4 homolog, U6 small
nuclear RNA associated (LSM4) genes on chromosome 19
(P= 3.861027). We selected the 64 independent SNPs most
significantly associated with log relative telomere length to
genotype in additional samples in the NHS (N=1345) and the
Women’s Genome Health Study (WGHS) (N= 1115) replication
populations. Estimates for all SNPs exhibited moderate to high
between-study heterogeneity (I2$0.50; Table S1). rs1978423 was
not associated with log relative telomere length in either
replication population (P$0.12). Two SNPs, rs4073054 at the
alipoprotein A-II (APOA2)/nuclear receptor subfamily 1, group I,
member 3 (NR1I3) locus on chromosome 1 and rs975504 near
dehydrogenase/reductase (SDR family) member 12 (DHRS12) and
a predicted non-coding RNA on chromosome 13, displayed
estimates similar to the associations from the initial GWAS
population with P values ,0.05 in the NHS replication
population, but not within the WGHS (Table S1; joint P values
of GWAS and replication populations are 1.761024 and
9.561024, respectively). rs7210405, ,24 kb downstream of the
cytohesin 1 (CYTH1) gene on chromosome 17, displayed the
smallest P value (0.01) within the WGHS population with a similar
estimate. However, this SNP was not associated with log relative
telomere length in the NHS replication population (joint
P= 1.461024).
We examined SNPs at the TERC and OBFC1 loci, which were
recently identified by published GWAS of telomere length [51,52].
Within our discovery GWAS and WGHS replication populations,
we examined associations with genotyped and imputed SNPs
(rs12696304, rs10936599, rs3772190, rs16847897) at the TERC
locus reported as significantly associated with telomere length in
prior GWAS. In our study populations, we found evidence for
associations between log relative telomere length and SNPs at this
locus, with the most significant association observed for the minor
allele [C] of rs16847897 (per allele b=20.03, joint P = 0.003).
Meta-analysis of our results for rs16847897 compared with study-
specific estimates from published GWAS generated a
P= 1.6610213 and displayed virtually no between-study hetero-
geneity (Table 2). Whereas Levy et al. [52] reported genome-wide
significant associations with SNPs in the OBFC1 gene, we did not
find evidence for associations between genotyped or imputed SNPs
at the OBFC1 locus and log relative telomere length in our study
(joint P$0.12). Meta-analysis of our results for SNPs at the OBFC1
locus with those reported by Levy et al. demonstrated high
between-study variability (Table 2). As we previously reported, we
did not find associations between log relative telomere length and
common genetic variants at the TERT-CLPTM1L, BICD1, and
DDX11 loci [55].
Discussion
Despite the high heritability of telomere length [17,40–45],
common variants associated with large effects have remained
elusive. We were unable to identify novel variants associated with
log relative telomere length with a high degree of confidence
among a total of 6,014 participants. The two most promising SNPs
identified by our study were rs4073054 (NHS GWAS, b=20.04,
P= 1.661024; PLCO GWAS, b=20.04, P = 0.041; NHS
replication, b=20.03, P = 0.01) and rs7210405 (NHS GWAS,
b=0.03, P = 0.006; PLCO GWAS, b=0.05, P= 0.005; WGHS
replication, b=0.03, P= 0.01), as 3 of our 4 study populations
displayed evidence of an association with log relative telomere
length. We had .80% power to detect b estimates as small as
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60.10 for SNPs with minor allele frequencies (MAF) of $0.15 in
our discovery GWAS population (N=3554). However, published
associations with relative telomere length suggest effect estimates
may be quite a bit smaller than 60.10. Our study was
underpowered to detect genome-wide significant associations
between log relative telomere length and SNPs of much weaker
effect. For example, adequate power to detect genome-wide
significant associations between SNPs at loci such as TERC that
have a MAF ,0.25, b,0.03, and log relative telomere length as
measured in our study would require a sample size of ,25,000
unrelated individuals. Even to reach the suggestive threshold of
a=161025, to detect an association with such a SNP would
require a sample size of 18,000 individuals, roughly 5 x greater
than the size of our initial GWAS population. Discovery of
additional loci with small effect sizes will be feasible once meta-
analyses of existing and future GWAS of telomere length are
conducted.
To date, only the TERC locus has been identified and replicated
in multiple independent populations for its association with
telomere length [51,52]. Although SNPs within the TERC locus
did not reach genome-wide significance in the discovery GWAS
population (N= 2917) of Codd et al. [51], rs16847897 fell
marginally outside of their pragmatic significance threshold
(P,161025) for replication. Due to the biological significance of
the locus, the authors examined and confirmed associations
between rs16847897 and a second SNP at the locus, rs12696304,
with telomere length in 3 replication populations. Levy et al. found
additional evidence for associations between SNPs at the TERC
locus and telomere length [52]. We found evidence for associations
with SNPs at the TERC locus, observing the strongest association
between the minor allele [C] of rs16847897 and log relative
telomere length (joint P = 0.003) with an effect size and direction
consistent with that of Codd et al. Similar to Codd et al., we did
not find associations between log relative telomere length and
SNPs at loci previously reported to be associated with telomere
length [43,49,50,58], including the OBFC1 locus recently identi-
fied by a similarly sized GWAS of telomere length [52].
If yeast genetic mapping studies are any indication [59,60],
hundreds of genes regulate human telomere length homeostasis.
Given that known telomere maintenance genes are highly
conserved [61] and mutations have deleterious consequences
[23], most functional common variants (. 5%) will likely have
small effects. Additionally, recent studies demonstrate that while
telomere length of offspring is significantly correlated with
maternal [62,63] and paternal [41,64,65] telomere lengths, the
paternal contribution appears to be much stronger [41,64,65] and
positive correlations have been observed between paternal age at
birth and offspring telomere length [41,66–68]. An influence of
imprinted genes in regulating telomere length could account for
these observations. By not controlling for parental origin of alleles
at imprinted loci, SNP effects, which are likely to be small to begin
with, would be underestimated and the power to detect
associations reduced [69]. For many GWAS populations,
including ours, determining the parental origin of alleles is not
feasible.
Evidence suggests cis-acting factors in subtelomeric regions
regulate telomere length. While chromosome-specific telomeres
tend to be similar between different individuals [48,70–73], allele
specific lengths are inherited [74] and may differ by more than
6 kb at the same telomere [75]. A substantial amount of genetic
diversity is provided by subtelomeric regions, which are riddled
with repetitive DNA, segmental duplications, and large copy
number polymorphisms including variable copy numbers of
functional genes. Knowledge of subterminal sequences is still
incomplete and the complexity within these regions has compli-
cated sequencing efforts [76] resulting in low coverage of such
regions on commercially available genome-wide genotyping arrays
[77].
Technical challenges further complicate the search for
genetic variants of telomere length. While the quantitative
PCR-based assay is the most economical, high-throughput
method for telomere length measurements in large epidemi-
ologic studies [78], values are relative representations of the
average telomere length. The telomere restriction fragment
(TRF) assay provides absolute values for the average, shortest,
and longest telomere lengths. However, TRF measurements
include variable amounts of the subtelomeric region, are time
and labor intensive, and require much more genomic DNA
than the PCR-based assay [79]. The single telomere length
analysis (STELA) assay is currently the most sensitive assay,
Table 1. Characteristics of GWAS and replication populations.
NHS GWAS PLCO GWAS NHS Replication WHS Replication
No. subjects 1944 1610 1345 1115
Mean age (range) 58.5 (43–70) 63.9 (55–74) 58.4 (43–69) 56.0 (45–82)
Smoking status (%)
Never 46.2 39.9 46.2 49.7
Former 40.5 50.1 41.9 36.7
Current 13.3 9.9 12.0 13.6
Pack-years (%)*
1–9 32.3 21.1 33.8 43.8
10–29 34.9 36.5 34.9 39.8
30+ 32.7 42.4 31.2 16.4
Mean log(RTL) (SD)
Cases 2.78 (0.35) 2.59 (0.55) 2.31 (0.35) 2.32 (0.26)
Controls 2.79 (0.35) 2.58 (0.58) 2.30 (0.34) 2.31 (0.25)
*among participants who have ever smoked.
doi:10.1371/journal.pone.0019635.t001
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developed with the potential to provide allele-specific telomere
lengths [75]. To date, telomere and allele-specific STELA
assays have only been developed for a very small fraction of
chromosome ends due to incomplete knowledge of subtelo-
meric regions [73].
The inability to capture the complexity of telomere length
regulation with a single measurement is a major obstacle to
GWAS efforts. Even the well established decline in telomere
length with increasing age is not a simple linear relationship.
Relatively fast rates of telomere attrition are observed during
childhood and adolescence. Attrition rates slow creating a plateau
from ,30 to 50 years of age followed by another decline in
telomere length from about age 50 to 80 [19,64,80,81]. It is
unknown whether temporally regulated genes and/or environ-
mental exposures are responsible for the change in attrition rates.
The age range of individuals in our GWAS population (Table 1)
and those of previously published studies [50–52] span these
different age periods potentially diluting telomere length
associations with variants that influence temporally regulated
genes.
Oxidative stress is thought to accelerate telomere attrition as
a result of damage to telomeric DNA, which is less efficiently
repaired [82]. Systemic exposures that contribute to oxidative
stress such as smoking [62,83,84] and obesity [54,84–87] have
been associated with shorter telomeres. Whereas, healthy
lifestyle choices promote a more stable telomere length
[81,86,88], possibly by increasing telomerase activity in cells
[89]. Evidence suggests environmental factors may take on a
more prominent role as determinants of telomere length with
increasing age [65,90], but the relationship with these
Figure 1. Log Quantile-Quantile (Q-Q) P value plot. The observed –log10 P values (Y-axis) of 519,076 SNPs from the pooled NHS and PLCO
GWAS data set adjusted for the principal components of genetic variation plotted against the expected –log10 quantile (X-axis). The dashed line
represents imputed P values.
doi:10.1371/journal.pone.0019635.g001
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exposures are not yet clearly defined as many studies fail to find
significant correlations between telomere length and smoking
[33,40,44,54,91], obesity [92,93], and/or physical activity
[92,94]. Since pack-years of smoking were significantly
correlated with relative telomere length among men of the
PLCO GWAS population, we adjusted for smoking character-
istics in all of our regression models. Although relative telomere
length in our prospectively collected blood samples was not
associated with breast [93] or prostate cancer [88], we adjusted
for case status to control for any potential effects of pre-clinical
disease on telomere length.
In summary, improved sequence maps and technical capabil-
ities are necessary to increase success in identifying and validating
common genetic variants associated with telomere length
homeostasis. Efforts will likely require meta-analyses of existing
and future telomere length GWAS to increase power to detect
common variants of small effects while stratifying by age groups
defined by attrition rate and controlling for environmental factors.
Table 2. Relative telomere length associations with SNPs at loci identified by published GWAS.
CGEMS GWAS* WGHS replication{ Meta-analysis{
Locus SNP WT/VT MAF b (s.e.) P value MAF b (s.e.) P value b (s.e.) P value Q I2 Pheterogeneity
TERC rs12696304 C/G 0.27 20.001 (0.01) 9.1E-01 0.26 20.03
(0.01)
3.4E-02 20.03 (0.004) 1.5E-14 15.35 0.54 3.2E-02
TERC rs10936599 C/T 0.25 20.02 (0.01) 1.9E-01 0.24 20.03
(0.01)
3.2E-02 20.03 (0.008) 2.8E-04 5.39 0.63 6.7E-02
TERC rs3772190 G/A 0.25 20.02 (0.01) 1.9E-01 0.24 20.03
(0.01)
3.8E-02 20.03 (0.008) 3.3E-04 5.40 0.63 6.7E-02
TERC rs16847897 G/C 0.28 20.03 (0.01) 2.1E-03 0.28 20.01
(0.01)
2.7E-01 20.03 (0.004) 1.6E-13 5.83 0.00 4.4E-01
OBFC1 rs11191839 G/A 0.35 20.001 (0.01) 9.2E-01 0.36 20.006
(0.01)
6.0E-01 20.003 (0.008) 0.66 0.10 0.00 7.5E-01
OBFC1 rs2902638 T/C 0.25 0.002 (0.01) 8.6E-01 0.25 20.03
(0.01)
2.6E-02 20.01 (0.009) 0.16 3.03 0.67 8.2E-02
OBFC1 rs10748858 T/G 0.41 20.004 (0.01) 7.1E-01 0.41 0.006
(0.01)
6.1E-01 0.0005 (0.008) 0.95 0.40 0.00 5.3E-01
OBFC1 rs2067832 T/C 0.50 20.002 (0.01) 8.4E-01 N/A
OBFC1 rs9325507 T/C 0.50 20.002 (0.01) 8.7E-01 0.50 0.006
(0.01)
6.1E-01 0.02 (0.007) 1.1E-02 19.45 0.74 1.6E-03
OBFC1 rs1980653 G/A 0.50 20.003 (0.01) 8.1E-01 0.50 0.006
(0.01)
6.1E-01 0.008 (0.007) 2.3E-01 25.17 0.80 1.0E-04
OBFC1 rs4918069 T/G 0.27 0.004 (0.01) 7.4E-01 0.29 20.03
(0.01)
4.3E-02 20.01 (0.008) 0.26 2.92 0.66 8.8E-02
OBFC1 rs2984132 T/C 0.40 20.002 (0.01) 8.5E-01 0.40 20.009
(0.01)
4.2E-01 20.005 (0.008) 0.49 0.21 0.00 6.5E-01
OBFC1 rs2487999 C/T 0.10 0.002 (0.02) 9.2E-01 0.10 0.04
(0.02)
3.4E-02 0.04 (0.01) 1.1E-04 19.94 0.75 1.3E-03
OBFC1 rs3752949 A/G 0.23 20.0006 (0.01) 9.6E-01 0.22 0.03
(0.01)
4.4E-02 0.01 (0.009) 0.18 2.24 0.55 1.3E-01
OBFC1 rs11191865 G/A 0.50 0.001 (0.01) 9.1E-01 0.49 20.006
(0.01)
6.1E-01 20.002 (0.008) 0.80 0.21 0.00 6.5E-01
OBFC1 rs1265164 G/A 0.14 20.008 (0.02) 6.0E-01 0.07 0.02
(0.02)
4.3E-01 20.0003 (0.01) 0.98 0.88 0.00 3.5E-01
OBFC1 rs9419958 C/T 0.14 20.006 (0.02) 7.1E-01 0.14 0.03
(0.02)
1.0E-01 0.03 (0.01) 5.3E-04 23.72 0.79 2.0E-04
OBFC1 rs9420907 A/C 0.14 20.004 (0.02) 7.8E-01 0.14 0.03
(0.02)
1.0E-01 0.03 (0.01) 4.3E-04 23.27 0.79 3.0E-04
OBFC1 rs4387287 C/A 0.15 20.005 (0.02) 7.3E-01 0.14 0.03
(0.02)
6.3E-02 0.04 (0.01) 1.1E-05 26.55 0.77 2.0E-04
OBFC1 rs17813699 G/A 0.10 20.005 (0.02) 7.5E-01 0.12 20.02
(0.02)
4.5E-01 20.01 (0.01) 0.48 0.18 0.00 6.7E-01
OBFC1 rs1342214 C/T 0.40 0.003 (0.01) 7.9E-01 0.41 20.007
(0.01)
5.2E-01 20.002 (0.008) 0.79 0.42 0.00 5.2E-01
*b estimates and P values derived from linear regression adjusted for age at blood collection, gender, an age-gender interaction term, smoking status, pack-year
categories of smoking, disease status, and principal components of genetic variation.
{b estimates and P values derived from linear regression adjusted for age at blood collection, smoking status, pack-year categories of smoking, disease status, and
principal components of genetic variation; N/A = SNP could not be imputed.
{Combined effect sizes and P values are calculated using a fixed-effect meta-analysis. Estimates in bold are based upon meta-analysis of the current study populations
along with those published by Codd et al. and Levy et al. Study-specific values from the published studies were used where available.
doi:10.1371/journal.pone.0019635.t002
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Materials and Methods
Ethics Statement
The NHS and WGHS study protocols were approved by the
Committee on Use of Human Subjects of the Brigham and
Women’s Hospital, Boston, MA. Institutional review boards at the
U.S. National Cancer Institute and the 10 screening centers
approved the PLCO protocol.
NHS breast cancer GWAS population
The NHS is a prospective cohort study of 121,700 female
registered nurses in 11 states in the United States who were 30–55
years of age at enrollment. In 1976 and biennially thereafter,
detailed information from participants was collected by self-
administered questionnaires. Participants in this study were
selected for a nested case-control study of telomere length and
postmenopausal breast cancer risk from the subcohort of 32,826
women who donated a blood sample in 1989–90 [93]. Eligible
cases consisted of postmenopausal women of European ancestry
with pathologically confirmed incident invasive breast cancer
diagnosed anytime after blood collection up to June 1, 2004 with
no prior diagnosis of cancer. Controls were randomly selected
postmenopausal women free of cancer and matched to cases
according to age, blood collection, and ethnicity. Completion of
the questionnaire and submission of the blood sample was
considered to imply informed consent. No significant difference
was observed for log relative telomere length between 1,122 cases
and 1,147 controls and no significant association with postmen-
opausal breast cancer risk [93]; therefore, we included telomere
length data from both breast cancer cases and controls for the
current study.
PLCO prostate cancer GWAS population
The PLCO Cancer Screening Trial is an ongoing randomized
trial with 154,942 persons aged 55 to 74 enrolled between
September 1993 and July 2001 from 10 screening centers
nationwide [95]. Detailed questionnaire data was collected from
all subjects at baseline. Participants provided blood and tissue
samples for etiologic studies of cancer [96] and all participants
provided written informed consent. Participants in this study were
male subjects selected for a nested case-control study of telomere
length, prostate cancer risk, and life-style variables [88]. Eligible
cases and controls consisted of non-Hispanic white men aged 55 to
74 who had been screened for prostate cancer (PSA test) prior to
October 1, 2003, completed a baseline questionnaire of cancer risk
factors, provided a blood sample 1 month to 3 years prior to
prostate cancer diagnosis for cases, and did not have a personal
history of cancer prior to study entry. All cases had pathologically
confirmed incident aggressive prostate cancer and a Gleason score
of $7. No significant difference was observed for relative telomere
length between 616 cases and 1,061 matched controls and no
significant association with aggressive prostate cancer risk [88];
therefore, we included telomere length data from both prostate
cancer cases and controls for the current study.
Replication populations
NHS participants in the replication phase of this study were
selected for a nested case-control study of telomere length and skin
cancer risk from the blood subcohort [97]. Eligible cases were
women of European ancestry with skin cancer diagnosed anytime
after blood collection up to June 1, 2000 with no prior diagnosis of
skin cancer. A common control series was randomly selected from
participants who gave a blood sample and were free of diagnosed
skin cancer up to and including the questionnaire cycle in which
the case was diagnosed. Controls were matched to cases by age
and ethnicity. The nested case-control study consisted of 218
melanoma cases, 285 cases with squamous cell carcinoma, 300
cases with basal cell carcinoma, and 870 matched controls. The
study protocol was approved by the Committee on Use of Human
Subjects of the Brigham and Women’s Hospital, Boston, MA.
The Women’s Genome Health Study (WGHS) is a prospective
cohort of female North American health care professionals
representing participants in the Women’s Health Study (WHS)
who provided a blood sample at baseline and consent for blood-
based analyses [98]. The WHS was a 262 trial beginning in 1992–
1994 of vitamin E and low dose aspirin in prevention of cancer
and cardiovascular disease with about 10 years of follow-up.
Follow-up continues in observational mode. Participants in the
WHS were 45 or older at enrollment and free of cardiovascular
disease, cancer or other major chronic illness and were followed
prospectively for the influence of random allocation of vitamin E
on cancer [99–101]. Additional information related to health and
lifestyle were collected by questionnaire throughout the WHS trial
and continuing observational follow-up. Participants in the current
analysis are individuals selected for a breast cancer case-control
study nested within the WGHS. Eligible cases consisted of women
of European ancestry diagnosed with pathologically confirmed
incident invasive breast cancer until March 7, 2000. Controls were
randomly selected participants who had given a blood sample, and
were free of diagnosed cancer. Controls were matched to cases
according to age, menopausal status, postmenopausal hormone
use at time of blood draw, and race/ethnicity. Written informed
consent was obtained from all women before their entry into the
trial.
Genotyping and quality control
As part of the CGEMS initiative, genotyping of the NHS
samples was conducted for the first stage of a three-stage GWAS of
breast cancer susceptibility using the Illumina HumanHap550
Infinium assay (Illumina, San Diego, CA), which contains SNPs
derived from the HapMap phase I and II data [102]. Genotyping
of PLCO samples for the prostate cancer susceptibility project
occurred in two parts [103]. Phase 1A used Illumina’s Sentrix
HumanHap300 assay and Phase 1B used the Sentrix Human-
Hap240 assay. For each cohort, samples with call rates ,90% and
single nucleotide polymorphism (SNP) assays with call rates under
90% were removed. Polymorphisms with a minor allele frequency
of ,1% were removed.
Genotyping of WGHS samples was performed using the
Illumina HumanHap300 Duo ‘‘+’’ chips or the combination of
the HumanHap300 Duo and iSelect chips. In either case, the
custom SNP content was the same; these custom SNPs were
chosen without regard to minor allele frequency (MAF) to saturate
candidate genes for cardiovascular disease as well as to increase
coverage of SNPs with known or suspected biological function, e.g.
disease association, non-synonymous changes, substitutions at
splice sites, etc. For quality control, all samples were required to
have successful genotyping using Illumina’s BeadStudio v. 3.3
software for at least 98% of the SNPs. Self-reported European
ancestry was verified on the basis of multidimensional scaling
analysis of identity by state using 1443 ancestry informative
markers in PLINK v. 1.06. The final data set retained SNPs with
MAF .1%, successful genotyping in 90% of the subjects, and
deviations from Hardy-Weinberg equilibrium not exceeding
P= 1026 in significance. Among the final 23,294 individuals of
verified European ancestry, genotypes for a total of 2,608,509
SNPs were imputed from the experimental genotypes and LD
relationships implicit in the HapMap r. 22 CEU samples.
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Genotyping of SNPs selected for replication in the NHS nested
skin cancer case-control data set was performed at the Dana
Farber/Harvard Cancer Center High-Throughput Genotyping
Core. Whole genome amplified DNA was genotyped using the
TaqmanH OpenArrayH Real-Time qPCR system (Applied
Biosystems Inc, Foster City, CA). Of the 64 SNPs selected for
replication, one failed to genotype. We removed 1 SNP with a call
rate ,90%. All SNPs were tested for deviation from Hardy-
Weinberg equilibrium within the entire skin cancer case-control
data set. We observed significant deviations for 3 SNPs at the
Bonferroni-adjusted P,0.0008, which were excluded from
analyses. We included 5% blinded quality control samples to
validate genotyping procedures; concordance for blinded samples
was .99%.
Relative telomere length measurement
Genomic DNA was extracted from peripheral blood leukocytes
using the QIAmp (Qiagen, Chatsworth, CA) 96-spin blood
protocol. DNA was quantified using either the Molecular Devices
96-well spectrophotometer (NHS, WGHS) or the Nanodrop SD-
1000 spectrophotometer (PLCO), and subsequently dried down
and resuspended to ensure accurate and uniform DNA concen-
trations. Relative telomere length was measured using a previously
described modified version [27] of the quantitative PCR-based
telomere assay [78]. Briefly, 5 ng of genomic DNA was dried down
in a 384-well plate and resuspended in 10 mL of either the
telomere (T) or 36B4 (S; single copy gene) PCR reaction mixture.
The Telomere reaction mixture consists of 1x QuantiTectH
SYBRH Green PCR Master Mix (Qiagen), 2 mM of DTT,
270 nM Tel-1b primer, and 900 nM Tel-2b primer. The
Telomere thermal cycling profile proceeds as follows: 95uC for
10 minutes then 30 cycles consisting of 95uC for 15 seconds and
54uC for 2 minutes. The 36B4 reaction mixture consists of 1x
QuantiTectH SYBRH Green PCR Master Mix, 300 nM 36B4u
primer, and 500 nM 36B4d primer. The 36B4 thermal cycling
profile proceeds as follows: 95uC for 10 minutes then 30 cycles
consisting of 95uC for 15 seconds and 58uC for 1 minute and 10
seconds. The threshold cycle (Ct) value for each reaction
represents the number of PCR cycles required to detect a signal
over background fluorescence and is inversely proportional to the
amount of starting DNA. Assuming 100% PCR efficiency, the
amount of PCR product exactly doubles with each cycle.
Triplicate reactions of each assay were performed on each sample
and the average of the 3 measurements was used for analyses.
Relative telomere length is calculated as the exponentiated ratio of
the telomere repeat copy number to single-gene copy number
(2-T/S) and represents the average telomeric DNA signal per
genome of an individual. Coefficients of variation (CV) for the
telomere and single-gene assay ranged from 0.66% to 3.02% and
0.56% to 2.07%, respectively.
Statistical analyses
Continuous relative telomere length was natural logarithm
transformed to satisfy the assumption of normality. We used
multivariable linear regression to analyze the additive effect of
each SNP (0, 1, or 2 copies of minor allele) on log relative telomere
length using the pooled NHS and PLCO GWAS data set. As log
relative telomere length is inversely associated with age in all
populations within this study [88,93,97] and significantly inversely
associated with smoking in the PLCO population, which included
a higher proportion of heavier smokers (Table 1) [88], the
regression model included age as a continuous variable, smoking
status, and pack-year categories of smoking (never, ,10, 10 to
,30, 30+) in addition to disease status. Since most published
studies find shorter telomere lengths among adult men compared
to women [42,43,62,65,92,104,105] as well as potentially faster
rates of telomere attrition among men [66,67,92], we included
gender and an age-gender interaction term in the initial GWAS
linear regression analyses. To control for potential confounding by
population stratification in the NHS GWAS, PLCO GWAS, and
WGHS replication data sets, we additionally adjusted for the top
principal components of genetic variation chosen for each study
after excluding any admixed individuals clearly not of European
descent. Principal components of genetic variation were calculated
with EIGENSTRAT software [106] as described in Hunter et al,
2007 [102]. All P values are two-sided. Statistical analyses were
performed with SAS (version 9.1; SAS Institute, Cary, NC) and
PLINK [107]. Power calculations were performed using
QUANTO [108].
Supporting Information
Table S1 Relative telomere length association results from the
GWAS and replication populations.
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